Literature DB >> 14633531

Preoperative interscalene block for elective shoulder surgery: loss of benefit over early postoperative block after patient discharge to home.

W Heinrich Wurm1, Mercedes Concepcion, Andrew Sternlicht, Jean Marie Carabuena, Gary Robelen, Leonidas C Goudas, Scott A Strassels, Daniel B Carr.   

Abstract

UNLABELLED: We performed a randomized, prospective, parallel-group, open-label, multicenter trial to compare the effects of pre- versus postoperative interscalene block using levobupivacaine on postoperative pain and analgesic requirements. One-hundred-two outpatients scheduled for elective shoulder surgery were randomized to receive 30 mL of 0.5% levobupivacaine either preoperatively (PRE group) or postoperatively (POST group). Analgesic outcome measures during the postoperative period were: (a). time to first request for analgesic medication after surgery, (b). pain intensity using the visual analog scale at rest and during arm movement, and (c). total analgesic consumption of nonsteroidal antiinflammatory drugs and opioids. The time to first analgesic request did not differ between treatment groups. However, mean maximum pain intensity scores during the day of surgery were significantly less for the PRE group than the POST group, both at rest (P = 0.001) and after movement (P = 0.004). The mean opioid administered during surgery was lower in the PRE than the POST group (P < 0.001). Levobupivacaine was well tolerated in both treatment groups, and no adverse reactions were related to this local anesthetic. In conclusion, preoperative interscalene block with levobupivacaine provided superior pain control for the first 12 h after surgery, but this benefit was not maintained during the week after discharge because the subjects assumed control of their own pain relief as outpatients. IMPLICATIONS: Preoperative interscalene block with levobupivacaine provides safe and effective analgesia for same-day elective shoulder surgery, but the benefit of this one-time intervention does not persist.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633531     DOI: 10.1213/01.ane.0000090320.46129.be

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

Review 1.  [Analgesia in shoulder, elbow and hand surgery].

Authors:  P Kasten; C J P Simanski; J P S Christian; T Volk; N Schmelzer-Schmied
Journal:  Orthopade       Date:  2008-10       Impact factor: 1.087

Review 2.  [Levobupivacaine for regional anesthesia. A systematic review].

Authors:  B Urbanek; S Kapral
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

Review 3.  Perioperative Pain Control in the Ambulatory Setting.

Authors:  Maunak V Rana; Ravi Desai; Lien Tran; D'Andra Davis
Journal:  Curr Pain Headache Rep       Date:  2016-03

4.  General health and knee function outcomes from 7 days to 12 weeks after spinal anesthesia and multimodal analgesia for anterior cruciate ligament reconstruction.

Authors:  Brian A Williams; Qainyu Dang; James E Bost; James J Irrgang; Steven L Orebaugh; Matthew T Bottegal; Michael L Kentor
Journal:  Anesth Analg       Date:  2009-04       Impact factor: 5.108

5.  Suprascapular nerve block as a method of preemptive pain control in shoulder surgery.

Authors:  J Jerosch; M Saad; M Greig; T Filler
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2008-03-28       Impact factor: 4.342

6.  Post operative pain management in shoulder surgery: Suprascapular and axillary nerve block by arthroscope assisted catheter placement.

Authors:  H Çağdaş Basat; D Hakan Uçar; Mehmet Armangil; Berk Güçlü; Mehmet Demirtaş
Journal:  Indian J Orthop       Date:  2016 Nov-Dec       Impact factor: 1.251

7.  Erector spinae plane block vs interscalene brachial plexus block for postoperative analgesia management in patients who underwent shoulder arthroscopy.

Authors:  Furkan Kapukaya; Mursel Ekinci; Bahadir Ciftci; Yunus Oktay Atalay; Birzat Emre Gölboyu; Ersin Kuyucu; Yavuz Demiraran
Journal:  BMC Anesthesiol       Date:  2022-05-12       Impact factor: 2.376

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.